Author： Adams M.E.
Publisher： Adis International
ISSN： 0114-5916
Source： Drug Safety, Vol.23, Iss.2, 2000-08, pp. : 115-130
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis
By Schmidt H. Woodcock B.G. Geisslinger G.
Drug Safety, Vol. 27, Iss. 3, 2004-01 ,pp. :
Access to resources
Recommend
A Risk-Benefit Assessment of Sildenafil in the Treatment of Erectile Dysfunction
By Vitezic D.
Drug Safety, Vol. 24, Iss. 4, 2001-01 ,pp. :
A Risk-Benefit Assessment of Alendronate in the Treatment of Involutional Osteoporosis
Drug Safety, Vol. 19, Iss. 2, 1998-08 ,pp. :